Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) passed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $4.75 and traded as high as $5.15. Adial Pharmaceuticals shares last traded at $5.05, with a volume of 83,319 shares changing hands.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on ADIL shares. Alliance Global Partners initiated coverage on shares of Adial Pharmaceuticals in a research report on Monday, August 3rd. They set a “buy” rating and a $11.00 price objective for the company. Wall Street Zen upgraded shares of Adial Pharmaceuticals to a “sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings lowered shares of Adial Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, October 12th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $8.33.
View Our Latest Analysis on ADIL
Adial Pharmaceuticals Stock Performance
The firm has a market capitalization of $13.28 million, a P/E ratio of -0.34 and a beta of 1.50. The firm has a 50 day moving average price of $4.75 and a two-hundred day moving average price of $3.28.
Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($11.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.03) by ($10.22).
About Adial Pharmaceuticals
Adial Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapeutics for addiction and related disorders. The company’s primary product candidate is AD04, an investigational formulation of ondansetron, a serotonin 5-HT3 receptor antagonist, being developed as a pharmacogenetically targeted treatment for alcohol use disorder.
AD04 is designed for people with alcohol use disorder who have specific genetic characteristics that may influence treatment response.
Recommended Stories
- Five stocks we like better than Adial Pharmaceuticals
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
